Oncoinvent ASA (0RU5.L)

Healthcare | Medical Pharmaceuticals
Income Statement (Quarterly) 2026-05-25 2025-06-30 2025-03-31 2024-12-31
Revenue 4,724,000 2,362,000 2,362,000 681,000
Cost of Revenue 0 0 0 105,000
Gross Profit 4,724,000 2,362,000 2,362,000 576,000
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 10,335,000 5,167,500 5,167,500 21,069,000
Operating Expenses 59,313,000 29,656,500 29,656,500 61,392,000
Operating Income -54,589,000 -27,294,500 -27,294,500 -60,711,000
Interest Expense 0 0 0 2,634,000
Income Before Tax -54,139,000 -27,069,500 -27,069,500 -53,444,000
Income Tax Expense 0 0 0 0
Net Income -54,139,000 -27,069,500 -27,069,500 -53,444,000
Per Share
EPS -1.38 -0.69 -0.69 -1.36
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2024-12-31 2023-12-31 2022-12-31
Revenue 848,000 354,000 389,000
Cost of Revenue 0 0 0
Gross Profit 848,000 354,000 389,000
Operating Expenses
R&D Expenses 0 0 0
SG&A Expenses 38,501,000 84,387,000 105,057,000
Operating Expenses 152,082,000 192,173,000 315,561,000
Operating Income -151,234,000 -191,819,000 -316,055,000
Interest Expense 4,700,000 578,000 11,514,000
Income Before Tax -139,282,000 -190,401,000 -302,122,000
Income Tax Expense 0 0 0
Net Income -139,282,000 -190,401,000 -302,122,000
Per Share
EPS -3.95 -13.30 -0.39
EPS Diluted 0.00 0.00 0.00
Balance Sheet (Quarterly) 2024-12-31 2023-12-31 2022-12-31
Assets
Cash and Cash Equivalents 140,155,000 155,969,000 150,804,000
Short Term Investments 0 452,000 0
Net Receivables 679,000 0 680,000
Inventory 0 0 0
Total Current Assets 154,543,000 173,904,000 166,663,000
Property Plant Equipment 1,254,000 431,000 43,000
Goodwill and Intangibles 0 0 0
Total Assets 155,796,000 174,335,000 166,706,000
Liabilities
Account Payables 12,924,000 18,605,000 29,634,000
Short Term Debt 884,000 418,000 0
Total Current Liabilities 32,277,000 46,859,000 77,933,000
Long Term Debt 818,000 0 275,000
Total Liabilities 33,095,000 46,859,000 78,208,000
Shareholders Equity
Retained Earnings 22,019,000 -189,234,000 0
Total Shareholders Equity 122,701,000 127,476,000 88,498,000
Balance Sheet (Annual) 2024-12-31 2023-12-31 2022-12-31
Assets
Cash and Cash Equivalents 140,155,000 155,969,000 150,804,000
Short Term Investments 0 452,000 0
Net Receivables 679,000 0 680,000
Inventory 0 0 0
Total Current Assets 154,543,000 173,904,000 166,663,000
Property Plant Equipment 1,254,000 431,000 43,000
Goodwill and Intangibles 0 0 0
Total Assets 155,796,000 174,335,000 166,706,000
Liabilities
Account Payables 12,924,000 18,605,000 29,634,000
Short Term Debt 884,000 418,000 0
Total Current Liabilities 32,277,000 46,859,000 77,933,000
Long Term Debt 818,000 0 275,000
Total Liabilities 33,095,000 46,859,000 78,208,000
Shareholders Equity
Retained Earnings 22,019,000 -189,234,000 0
Total Shareholders Equity 122,701,000 127,476,000 88,498,000
Cash Flow Statement (Quarterly) 2024-12-31 2023-12-31 2022-12-31
Operating Activities
Net Income -139,282,000 -190,401,000 -302,122,000
Depreciation & Amortization 456,000 223,000 883,000
Stock Based Compensation 5,709,000 3,135,000 3,466,000
Change in Working Capital -11,636,000 -33,389,000 10,179,000
Operating Cash Flow -153,242,000 -225,101,000 -285,282,000
Investing Activities
Capital Expenditure 0 0 0
Investments 0 0 0
Investing Cash Flow 3,688,000 3,055,000 299,000
Financing Activities
Debt Repayment -438,000 0 -307,000
Common Stock Issued/Repurchased 138,874,000 262,048,000 3,211,000
Dividends Paid 0 0 0
Financing Cash Flow 129,610,000 224,884,000 2,904,000
Summary
Free Cash Flow -153,242,000 -225,101,000 -285,282,000
Net Change in Cash -16,266,000 5,618,000 -285,842,000
Cash Flow Statement (Annual) 2024-12-31 2023-12-31 2022-12-31
Operating Activities
Net Income -139,282,000 -190,401,000 -302,122,000
Depreciation & Amortization 456,000 223,000 883,000
Stock Based Compensation 5,709,000 3,135,000 3,466,000
Change in Working Capital -11,636,000 -33,389,000 10,179,000
Operating Cash Flow -153,242,000 -225,101,000 -285,282,000
Investing Activities
Capital Expenditure 0 0 0
Investments 0 0 0
Investing Cash Flow 3,688,000 3,055,000 299,000
Financing Activities
Debt Repayment -438,000 0 -307,000
Common Stock Issued/Repurchased 138,874,000 262,048,000 3,211,000
Dividends Paid 0 0 0
Financing Cash Flow 129,610,000 224,884,000 2,904,000
Summary
Free Cash Flow -153,242,000 -225,101,000 -285,282,000
Net Change in Cash -16,266,000 5,618,000 -285,842,000